Dear Mr. Dundler:
As directed by Prof. Basie von Solms, I am herewith sending the following
attachment to be distributed to TC Chairs before they leave for
Toulouse....
_________________________________
Dear Basie & TC Chairs:
I have been thinking about suggesting a change in bylaws to accomplish the
following:
Any TC can establish SIG's Special Interest Groups, which would be treated
like Working Groups, but must convert either to a WG or disband after 5
years.
Any TC or Working Group can establish a Task Force with a specific study
mission, limited life span and be disbanded.
The Specialist Group can have Working Groups, but must convert either to a
TC or be dissolved.
I've had some feedback from Leon Strous and we generated the following
schematic (see attachment 1).
Attachment 1 :
Second, I generated (not being a Parliamentarian) suggestions to changes
in the bylaws (see attachment 2)
Attachment 2 :
Thirdly, I received suggestions relating to the bylaw changes from Leon
Strous (see his comments & bylaw changes below)
Dear Gus,
in the meantime I took a closer look at the proposed changes to the
Statutes & Bylaws. I have made some additional changes, also in the order
of the articles to make it a more logical sequence. In order not to
confuse a lot of red coloured changes, I have used only red for a part
that needs additional text / work.
The most notable changes concern the membership of a SG, this cannot be
exactly the same as for a TC, especially not at the start of it. Let me
know what you think of my proposal.
A suggestion which relates to your powerpoint figure is the name of a
working group of an SG. I would just call this a working group and not a
Special Working Group.
kind regards,
Leon
Attachment 3 :
Gustav
ITN/PD
Visit the CAx R&T website at: http://roadmap/d2710
Dear Mr. Dundler:
As directed by Prof. Basie von Solms, I am herewith sending the following
attachment to be distributed to TC Chairs before they leave for Toulouse.
____________________________
Dear Prof. von Solms & TC5 Chairs:
The attachment contains a Title Change for TC5 from Computer Applications
in Technology to Information Technology Applications, as well as updated
Aims and Scopes for discussion.
Gustav
ITN/PD
Visit the CAx R&T website at: http://roadmap/d2710
Dear Mr. Dundler:
As directed by Prof. Basie von Solms, I am herewith sending the following
attachment to be distributed to TC Chairs before they leave for
Toulouse....
_________________________________
Dear TC Chairs:
Please find the revised version, by Prof. Roode, of the International
Federation for Information Processing Guidelines for Responsibilities of
National Representatives to IFIP Technical Committees for discussion in
Toulouse.
Gus Olling
TC5 Chair
========================================================
PAIN MANAGEMENT 2004 - Analysing Regulatory, Commercial
& Pharmaceutical Practices
8th and 9th September 2004 (Workshop 7th September 2004)
Marriott Kensington Hotel, London
========================================================
**FULL AGENDA BELOW** - PDF COPY OF THE BROCHURE NOW AVAILABLE
Visiongain b2b Conferences is pleased to announce that 'Pain Management 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices ' will be run in early September this year. This event will follow up on the success of 'Future Pain Drugs 2003' but as a case-study based event will focus more on future targets and market development. The agenda is now complete, a list of confirmed speakers and topics can be found below.
KEY THEMES:
- Identify Key Market Segments and Profit From Emerging Trends in Pain Therapeutics
- Clinical Models for Pain- Learn Which Will Suit Your Company Needs
- Discover How Drug Delivery Systems will Shape the Future of Pain Therapeutics, Highlighting Lucrative Market Opportunities
- Learn From the Best Practice Case Studies such as: Actiq- SPM 927- GPI 5693- Imitrax- Tramadol - Buprenorphine- Sativex
- Examine the Key Legal and Regulatory Issues in the Development of Novel Pain Therpaeutics
- Assess the Advances in Cannabis Based Medicines- R&D and Delivery Technologies
- Advice on Scheduling of Centrally Acting Analgesics
CONFIRMED SPEAKERS
**Dr. Peter McIntyre, Lab Head/ Head of Exploratory Pain Projects, Novartis
**Dr. Sharon Bingham, Somatic Pain - Pain Research, Neurology CEDD, GlaxoSmithKline
**Gary Liversidge, Senior Director, Project Planning and Management, Elan
**Praveen Anand, Professor Clinical Neurology, Imperial College
**Dr. Stuart Bevan, Director, Novartis Institute for Medical Research
**Dr. Jeffry Vaught, Senior Vice President & President, R&D Division, Cephalon
**Dr. Christine Rauschkolb, Program Director/ Medical Scientist Pain, Schwarz Bioscience
**Dr. Tony Ho, Associate Director, Merck
**Dr Mike Reed, Director Branded Product Marketing International, Alpharma
**Dr. Krystyna Wozniak, Lead Scientist on NAALADase program, Guilford Pharmaceuticals Inc
**Dr. Stephen Wright, Director of R&D, GW Pharma Ltd
**Dr. Francesco Impagnatiello, Pharmacologist- Pain Research, NicOx
WHO SHOULD ATTEND
-Medical Director
-Divisional VP, Neurological & Urological
-Pain, Migraine Research
-Divisional VP, Immunosciences Development
-Inflammatory Therapeutics
-Respiratory RA Disease Group
-Head of clinical development/ VP clinical development
-Head of clinical research, CNS
-Head of R&D (Pain/CNS/Depression)
-CNS clinical project management
-Head of CNS therapeutics
-Chief Technical Officer
-Director, Preclinical R&D
-Vice President, Research
-Vice President, Research and Development
2003's TESTIMONIALS
"interesting topics, well organised"
"excellent conference"
"very good, covering a wide aspect of pain therapy"
"topline overview of the field"
"topical + scientifically sound"
"exceeded expectations, high scientific level"
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are limited, please call or email me now to secure your place
- PRICING -
Attend the:
** Conf. + pre conf. workshop GBP 1600.00 Plus VAT
** Conference only Fee: GBP 1299.00 Plus VAT
** Pre conference workshop only Fee: GBP 650.00 Plus VAT
- BOOKINGS -
Booking is easy, simply contact Joe Stone on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:joe.stone@visiongain.com
Terms and conditions apply - see below.
Kind regards,
Joe Stone
Account Manager
Visiongain b2b Conferences
Tel: +44 (0) 20 8767 6711
http://www.b2b-conferences.com
mailto:Joe.stone@visiongain.com
==============================================================================================
-----------------
** FULL AGENDA **
-----------------
PRE-CONFERENCE INTERACTIVE WORKSHOP - Tuesday 7th September 2004
LifeSpan Biosciences: The Pathology of Pain
Led by: Dr. Julian Beesley, VP European Sales & Business Development, LifeSpan Biosciences, Inc
-Molecular pathology approach and studies at LifeSpan
-Industrialization of the molecular pathology process
-Drug targets, selection of targets and receptor localisation
-Automated Lifespan Imaging and Analysis System (ALIAS)
=====================================
Day One Wednesday 8 th September 2004
=====================================
09:00 Registration and coffee
09:30 Opening remarks from the Chair
MODELS AND TARGETS
09:40 Developments in Pain Therapy- Ventures for Your
Company
* Molecular targets in pain research- past, present and future
* Research methodologies- how can you implement them?
* Research tools and how best to use them
* Balancing risk in the research portfolio - gain positive results
for your company
* Outlook: new targets for pain relief ligands and the future for
pain therapies in the clinic
Dr. Peter McIntyre
Lab Head/ Head of Exploratory Pain Projects
Novartis
10:20 Human Pain Models- How Can You Maximise Their Use?
* Limitations of current animal models- find how they relate to
human data
* Clinical needs- pathophysiological and imaging surrogates
* Lessons to learn from failed clinical trials- gain knowledge on
avoiding and overcoming similar problems
* How to increase the success of Phase II clinical trials
* Target validation: novel pain targets in human chronic states
* How to select patients for successful POC clinical trials
* New models for assessing pain- examples and how to
implement them
Praveen Anand
Professor Clinical Neurology
Imperial College
11:00 Morning Coffee
11:20 How to Use Nitric Oxide (NO) Properties to Achieve Effective Therapeutics
* NO-releasing analgesics: a novel class of drugs for the treatment of pain
* The contribution of NO-releasing moiety to commonly-used analgesics: rationale and potential added values
* Case studies: NO-releasing paracetamol/NO-releasing gabapentin
* Potential mechanisms of action of NO in pain/inflammation
Dr. Francesco Impagnatiello
Pharmacologist- Pain Research
NicOx
12:00 Find New Targets and Pointers to Validate them
* Pain signalling pathways- where can you find new targets?
* Pharmacological mechanisms of pain
* Pain platforms- detailing the molecular basis
* Target validation- strategies for success
* Target identification vs target validation
* Target treatment- is there a need and future ventures for your
company
Dr. Ray Scraggs
Pharmaceutical Consultant
visiongain Consultancy
12:40 Lunch
14:00 Using Animals- How to make them Disease Relevant
Pain Models?
* Classical versus novel approaches to pain models- what will
suit your needs?
* Changing views on behavioural versus functional endpoints
* How you can validate a model- pointers
* Difficulties in assessing pain in animals- how effective are
these models and how to improve them
* Screening putative analgesics
* How to use animal models for causes of pain
Dr. Sharon Bingham
Somatic Pain - Pain Research
Neurology CEDD
GlaxoSmithKline
14:40 The Role of Vanilloid Receptors in Nociception
* Expression of vanilloid receptors
- how to demonstrate the existence of specific vanilloid
receptors
* Molecular and functional characterisation of cloned VR1
* VR1 as a pivotal transducer
* Comparison of VR1 and native receptors- what advantaged
can you make use of?
Dr. Stuart Bevan
Director
Novartis Institute for Medical Research
15:20 Afternoon Tea
15:40 Advice on Scheduling of centrally acting analgesics
* The rationale of scheduling- how and why?
* International and national conventions and laws- what to
foresee as a result
* Development and registration of controlled drugs
* Marketing of controlled drugs- recommendations
* Case Studies: Tramadol and buprenorphine
Dr. Franz Philipp Gerstheimer
Corporate Medical and Scientific Services
Grunenthal GmbH
OVERCOMING CANCER PAIN
16:20 CASE STUDY: Actiq, the only FDA Approved Drug for
Breakthrough Cancer Pain
* Temporal characteristics of persistence and breakthrough pain
* Actiq's novel oral transmucosal system- how does it work?
* Parmacokinetics and pharmacodynamics of oral transmucosal
fentanyl delivery
* What are the benefits of oral transmucosal delivery?
* Onset of action and duration of effect
* Side effects and how you can overcome them
Dr. Jeffry Vaught
Senior Vice President & President, R&D Division
Cephalon
17:00 Questions and Discussion
17:20 Summation of day one from conference chair
====================================
Day Two Thursday 9 th September 2004
====================================
09:00 Registration and Coffee
09:30 Opening remarks from the Chair
NEUROPATHIC PAIN MARKET
09:40 CASE STUDY: Pharmacology of SPM 927 and its
Relevance to Clinical Practice
* Basic pharmacology of SPM 927
* Efficacy of SPM 927 in an animal model for diabetic
neuropathy
* Pharmacological profiling in further animal models for chronic
pain- what can you impliment in practice?
* This anti-convulsant drug's mechanism of action
Dr. Bettina Beyreuther
Senior Scientist Pharmacology- Preclinical Development
Schwarz BioSciences
10:20 CASE STUDY: SPM 927 - A Novel Promising Pain Treatment
* Human pharmacology of SPM 927
* 'First in patient' evaluation- where can improvements be made?
* Efficacy and tolerability in diabetic neuropathy
* Efficacy in other indications
Dr. Christine Rauschkolb
Program Director/ Medical Scientist Pain- Clinical Development
Schwarz BioSciences
11:00 Morning Coffee
11:20 NAALADase Inhibition: a Novel Mechanism for Treating Neuropathic Pain and Peripheral Neuropathy
* Selective Blockade of excitotoxic glutamate
* Efficacy in multiple animal models of peripheral neuropathy, neuropathic pain, stroke, and ALS
* Phase 1 trial results
Krystyna Wozniak
Lead Scientist on NAALADase Program
Guilford Pharmaceutical Inc
HEADACHE AND MIGRAINE PAIN- PRODUCT ANALYSIS
VIOXX - First Coxib Approved of Acute Migraine
* Migraine - a serious debilitating disorder
* Current acute migraine therapy
* Efficacy of rofecoxib in acute migraine therapy
* Safety of rofecoxib in acute migraine therapy
* Role of rofecoxib in acute migraine therapy
Dr. Tony Ho
Associate Director
Merck
12:40 Lunch
MARKET OPPORTUNITIES
14:00 CASE STUDY: The NanoCrystal Technology Approach
* How to overcome solubility issues for pain therapeutics
* Technology performance advantages
* Can it be used as a life cycle management tool?
* A commercialised, validated solution
Gary Liversidge
Senior Director, Project Planning and Management
Elan
14:40 CASE STUDY: Peptrans, a Novel Approach to Brain
Delivery
* The BBB and drug delivery in the CNS
* Pep:trans mechanism of action
* Delivery of analgesics- an effective solution?
* Potential within the market- where can you capture a share of
the market?
Jamal Temsamani
Director, Preclinical R&D
Synt:em
15:20 Afternoon Tea
15:40 Cannabis Based Medicines- How to Optimise Pain
Treatment
* Clinical indication and pain management with cannabinoids
* GW cultivation license, possession and supply for medical
research
* R&D clinical trials- quality, safety, efficacy and phase I-III trials
* Drug delivery technologies- oro mucosal sprays, oral
formulations and inhalers
* Limitations of cannabinoid therapies- where can you fail?
* Case study: update on Sativex
Dr. Stephen Wright
Director of R&D
GW Pharma Ltd
16:20 Regulatory Limitations- Use and Distribution of Narcotic
Drugs
* Medical narcotics, the potential for misuse
* The prevention of drug abuse- new methods and control
* National drug policies- updates and how to enforce them
* Control of substances- how it limits availability for
legitimate use
Dr. Mike Reed
Director Branded Product Marketing International
Alpharma
17:00 Generics: Identifying and Overcoming the Legal and
Regulatory Challenges of the Future
* The latest developments affecting the generic drug sector and
pharmaceutical legislation
* Important legal issues- current scientific initiatives
* Potential solutions to current challenges
* Key regulatory issues in Europe
Mr. Horst Kastrup
VP Worldwide Regulatory Affairs
Viatris
17:40 Questions and Discussion
18:00 Chairman summation
18:10 Close of Conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
#####################################################################################
This email has been scanned by MailMarshal, an email content filter.
#####################################################################################
Due to multiple requests and following the Globecom 2004 guidelines we are
extending the deadline to JULY 15th 2004.
1st IEEE International Workshop on Networking Issues in Multimedia
Entertainment (NIME'04)
CALL FOR PAPER AT: http://nime04.csr.unibo.it/nime04
IEEE Workshop @ GLOBECOM 2004
November 29th 2004
Dallas, TX, USA
EXTENDED SUBMISSION DEADLINE July 15th 2004.
The papers accepted will be published in the workshop proceedings (by IEEE)
and made available on line through IEEE-Explorer.
Our Sincere apologies if you receive multiple copies.
Regards
Giovanni Pau, Marco Roccetti & S.S. Lee
========================================
"... Loving might be a mistake but it's worth making
Don't let some hell bent heart leave you bitter ..."
(Lee Ann Woomak - I hope you dance)
========================================
Giovanni Pau, PhD
UCLA - Computer Science Department
3803A BH, Boelter Hall
Los Angeles, 90095 CA
Ph: (310) - 206-3212; Cell: (310) - 617-4728
Fax: (310)- 825-7578
http://www.cs.ucla.edu/~gpau
Dear all,
please find enclosed the minutes of meeting 2004/1 in Athens
(May 14+15, Athens),
Thanks once again to:
- Ioannis Stavrakakis for the perfect organisation of the meeting
- Peter Radford for the careful writing of the meeting minutes.
Best regards
Otto
Dear all,
you will remember from the discussions in Athens and/or
from the minutes that we have to use at least 20 percent of the
TC6 fund per year (which is above a threshold value of 15.000 EURO)
or the non used part will be capped and put into the global budget
of IFIP. Expenditures of this kind are for student travel, best paper
awards, tutorial speaker's cost etc, *not* for operational expenses.
According to the allocations of the past + some new requests (which
sometimes came quite unexpectedly and which will have to be
approved at our meeting 2004/2 in Bangkok!)
I have submitted a request for 22.500 EURO (+5.000 EURO for
operational expenses). This is well above our minimum of 13.000 EURO
and it is questionable whether TC6 can continue to spend so much
money every year.
Please find below a list of requests together with some explanations.
Best regards
Otto
----------------------------------
----------------------------------
Event funded requests of TC6 for 2005:
IFIP TC6 requests a budget of 27.500 EURO for 2005.
This is split up into (see below):
- student travel grants 12.500 EURO
- best paper awards 6.000 EURO
- tutorial speakers cost 4.000 EURO
- operational expenses 5.000 EURO
The fund balance of TC6 was roughly 80.000 EURO,
i.e. 65.000 EURO above the threshold of 15.000 EURO.
We have to use at least 20 percent of that fund, i.e.
13.000 EURO, for nonoperational expenses.
The planned expenditure of 27.500 - 5.000 = 22.500 EURO
is well above the lower limit of 13.000 EURO.
----------------------------------------
Use of the budget:
Student travel grants Best paper awards
(750 EURO each) (500 EURO each)
WG 6.1: Middleware: 2 (= 1.500 EURO) 1 (= 500 EURO)
FORTE 1 (= 750 EURO) 1 (= 500 EURO)
TESTCOM 1 (= 750 EURO) 1 (= 500 EURO)
WG 6.2: Networking 2 (= 1.500 EURO) 1 (= 500 EURO)
MWCN 1 (= 500 EURO)
WG 6.4: WWW 3 (= 2.250 EURO) 1 (= 500 EURO)
WG 6.6: IM 2005 2 (= 1.500 EURO) 1 (= 500 EURO)
NOMS 2 (= 1.500 EURO) 1 (= 500 EURO)
MMNS 1 (= 500 EURO)
DSOM 1 (= 500 EURO)
WG 6.8: PWC 2 (= 1.500 EURO) 1 (= 500 EURO)
WG 6.10: ONDM 2 (= 1.500 EURO) 1 (= 500 EURO)
Subtotal: 12.750 EURO 6.000 EURO
WG 6.9: Request of 4.000 EURO for tutorialists travel
to LANC 2005 in Cali (Colombia)
Operational Expenses: 5.000 EURO
Total (Event funded expenses + tutorial speaker cost +
Operational expenses)
27.750 EURO
This is higher than the budget planned for 2004 (which was 25.000 EURO).
The reasons:
- NOMS was forgotten but got the funds promise in 2004.
- WWW got a higher promise than indicated in the meeting minutes
of meeting 2003/2 (3 student travels instead as 2)
- ONDM came recently ?in a fully unexpected way"
with a request of 2 student grants + 1 PBA.
On the other hand some conferences of 2004 will not be hold in 2005
(INTELLCOMM,...) and thus student travels + tutorial speakers cost were
not claimed for 2005.
However, we cannot exclude that some additional requests are still
to come.
In the future it will have to be discussed whether we can afford such a
high amount of cost; especially the student travel cost might be reduced.
To my opinion, a conference should return to TC6 at least the cost which
it claims from TC6 for support.
A positive example of that was NOMS'94 which got 2.000 EURO
(see above) but which returned 6.300 EURO to IFIP.
The allocation is preliminary! In Bangkok we will have to decide whether
we accept the new request from ONDM, the increased claim
for WWW etc.
========================================================
PAIN MANAGEMENT 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices
8th and 9th September 2004 (Workshop 7th September 2004)
Marriott Kensington Hotel, London
========================================================
**FULL AGENDA BELOW** - PDF COPY OF THE BROCHURE NOW AVAILABLE
please email mailto:lorraine.lescure@visiongain.com for a PDF brochure.
Visiongain b2b Conferences is pleased to announce that 'Pain Management 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices ' will be run in early September this year. This event will follow up on the success of 'Future Pain Drugs 2003' but as a case-study based event will focus more on future targets and market development. The agenda is now complete, a list of confirmed speakers and topics can be found below.
KEY THEMES:
- Identify Key Market Segments and Profit From Emerging Trends in Pain Therapeutics
- Clinical Models for Pain- Learn Which Will Suit Your Company Needs
- Discover How Drug Delivery Systems will Shape the Future of Pain Therapeutics, Highlighting Lucrative Market Opportunities
- Learn From the Best Practice Case Studies such as: Actiq- SPM 927- GPI 5693- Imitrax- Tramadol - Buprenorphine- Sativex
- Examine the Key Legal and Regulatory Issues in the Development of Novel Pain Therpaeutics
- Assess the Advances in Cannabis Based Medicines- R&D and Delivery Technologies
- Advice on Scheduling of Centrally Acting Analgesics
CONFIRMED SPEAKERS
**Dr. Peter McIntyre, Lab Head/ Head of Exploratory Pain Projects, Novartis
**Dr. Sharon Bingham, Somatic Pain - Pain Research, Neurology CEDD, GlaxoSmithKline
**Gary Liversidge, Senior Director, Project Planning and Management, Elan
**Praveen Anand, Professor Clinical Neurology, Imperial College
**Dr. Stuart Bevan, Director, Novartis Institute for Medical Research
**Dr. Jeffry Vaught, Senior Vice President & President, R&D Division, Cephalon
**Dr. Christine Rauschkolb, Program Director/ Medical Scientist Pain, Schwarz Bioscience
**Paul Strijbos, Neurology and Drug Discovery, GlaxoSmithKline
**Dr Mike Reed, Director Branded Product Marketing International, Alpharma
**Dr. Krystyna Wozniak, Lead Scientist on NAALADase program, Guilford Pharmaceuticals Inc
**Dr. Stephen Wright, Director of R&D, GW Pharma Ltd
**Dr. Francesco Impagnatiello, Pharmacologist- Pain Research, NicOx
WHO SHOULD ATTEND
-Medical Director
-Divisional VP, Neurological & Urological
-Pain, Migraine Research
-Divisional VP, Immunosciences Development
-Inflammatory Therapeutics
-Respiratory RA Disease Group
-Head of clinical development/ VP clinical development
-Head of clinical research, CNS
-Head of R&D (Pain/CNS/Depression)
-CNS clinical project management
-Head of CNS therapeutics
-Chief Technical Officer
-Director, Preclinical R&D
-Vice President, Research
-Vice President, Research and Development
This event will provide unrivalled opportunities to promote your brand to an audience of senior level delegates. Decision makers from all aspects of the messaging & media markets will be in attendance, what better way to elevate your product? We are continually recognised for providing innovative and effective means to support your marketing requirements through sponsorship and exhibitions at our leading events. Options include:
*Full Conference Sponsorship
*Exhibition Stands & Booths
*Cocktail Reception Sponsorship
*Promotional Inserts in Delegate Folders
*Conference Bag Sponsorship
Whatever your budget, whatever your requirements we can find you a way to place your brand at Developments, Outlook and Markets for Pain 2004.
If you would like further information on how you can become involved in this event then please do not hesitate to get in touch with:
Lorraine Lescure
Account Manager - Conference Division
Visiongain B2B Conferences
Tel. +44(0)20 8767 6711
Fax. +44(0)20 8767 5001
mailto:lorraine.lescure@visiongain.com
www.b2b-conferences.com
B2B Conferences is part of the Visiongain Group
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are limited, please call or email me now to secure your place
- PRICING -
Attend the:
** Conf. + pre conf. workshop GBP 1600.00 Plus VAT
** Conference only Fee: GBP 1299.00 Plus VAT
** Pre conference workshop only Fee: GBP 650.00 Plus VAT
- BOOKINGS -
Booking is easy, simply contact Lorraine Lescure on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:lorraine.lescure@visiongain.com
Terms and conditions apply - see below.
==============================================================================================
-----------------
** FULL AGENDA **
-----------------
PRE-CONFERENCE INTERACTIVE WORKSHOP - Tuesday 7th September 2004
LifeSpan Biosciences: The Pathology of Pain
Led by: Dr. Julian Beesley, VP European Sales & Business Development, LifeSpan Biosciences, Inc
-Molecular pathology approach and studies at LifeSpan
-Industrialization of the molecular pathology process
-Drug targets, selection of targets and receptor localisation
-Automated Lifespan Imaging and Analysis System (ALIAS)
=====================================
Day One Wednesday 8 th September 2004
=====================================
09:00 Registration and coffee
09:30 Opening remarks from the Chair
MODELS AND TARGETS
09:40 Developments in Pain Therapy- Ventures for Your
Company
* Molecular targets in pain research- past, present and future
* Research methodologies- how can you implement them?
* Research tools and how best to use them
* Balancing risk in the research portfolio - gain positive results
for your company
* Outlook: new targets for pain relief ligands and the future for
pain therapies in the clinic
Dr. Peter McIntyre
Lab Head/ Head of Exploratory Pain Projects
Novartis
10:20 Human Pain Models- How Can You Maximise Their Use?
* Limitations of current animal models- find how they relate to
human data
* Clinical needs- pathophysiological and imaging surrogates
* Lessons to learn from failed clinical trials- gain knowledge on
avoiding and overcoming similar problems
* How to increase the success of Phase II clinical trials
* Target validation: novel pain targets in human chronic states
* How to select patients for successful POC clinical trials
* New models for assessing pain- examples and how to
implement them
Praveen Anand
Professor Clinical Neurology
Imperial College
11:00 Morning Coffee
11:20 How to Use Nitric Oxide (NO) Properties to Achieve Effective Therapeutics
* NO-releasing analgesics: a novel class of drugs for the treatment of pain
* The contribution of NO-releasing moiety to commonly-used analgesics: rationale and potential added values
* Case studies: NO-releasing paracetamol/NO-releasing gabapentin
* Potential mechanisms of action of NO in pain/inflammation
Dr. Francesco Impagnatiello
Pharmacologist- Pain Research
NicOx
12:00 Find New Targets and Pointers to Validate them
* Pain signalling pathways- where can you find new targets?
* Pharmacological mechanisms of pain
* Pain platforms- detailing the molecular basis
* Target validation- strategies for success
* Target identification vs target validation
* Target treatment- is there a need and future ventures for your
company
Dr. Ray Scraggs
Pharmaceutical Consultant
visiongain Consultancy
12:40 Lunch
14:00 Using Animals- How to make them Disease Relevant
Pain Models?
* Classical versus novel approaches to pain models- what will
suit your needs?
* Changing views on behavioural versus functional endpoints
* How you can validate a model- pointers
* Difficulties in assessing pain in animals- how effective are
these models and how to improve them
* Screening putative analgesics
* How to use animal models for causes of pain
Dr. Sharon Bingham
Somatic Pain - Pain Research
Neurology CEDD
GlaxoSmithKline
14:40 The Role of Vanilloid Receptors in Nociception
* Expression of vanilloid receptors
- how to demonstrate the existence of specific vanilloid
receptors
* Molecular and functional characterisation of cloned VR1
* VR1 as a pivotal transducer
* Comparison of VR1 and native receptors- what advantaged
can you make use of?
Dr. Stuart Bevan
Director
Novartis Institute for Medical Research
15:20 Afternoon Tea
15:40 Advice on Scheduling of centrally acting analgesics
* The rationale of scheduling- how and why?
* International and national conventions and laws- what to
foresee as a result
* Development and registration of controlled drugs
* Marketing of controlled drugs- recommendations
* Case Studies: Tramadol and buprenorphine
Dr. Franz Philipp Gerstheimer
Corporate Medical and Scientific Services
Grunenthal GmbH
OVERCOMING CANCER PAIN
16:20 CASE STUDY: Actiq, the only FDA Approved Drug for
Breakthrough Cancer Pain
* Temporal characteristics of persistence and breakthrough pain
* Actiq's novel oral transmucosal system- how does it work?
* Parmacokinetics and pharmacodynamics of oral transmucosal
fentanyl delivery
* What are the benefits of oral transmucosal delivery?
* Onset of action and duration of effect
* Side effects and how you can overcome them
Dr. Jeffry Vaught
Senior Vice President & President, R&D Division
Cephalon
17:00 Questions and Discussion
17:20 Summation of day one from conference chair
====================================
Day Two Thursday 9 th September 2004
====================================
09:00 Registration and Coffee
09:30 Opening remarks from the Chair
NEUROPATHIC PAIN MARKET
09:40 CASE STUDY: Pharmacology of SPM 927 and its
Relevance to Clinical Practice
* Basic pharmacology of SPM 927
* Efficacy of SPM 927 in an animal model for diabetic
neuropathy
* Pharmacological profiling in further animal models for chronic
pain- what can you impliment in practice?
* This anti-convulsant drug's mechanism of action
Dr. Bettina Beyreuther
Senior Scientist Pharmacology- Preclinical Development
Schwarz BioSciences
10:20 CASE STUDY: SPM 927 - A Novel Promising Pain Treatment
* Human pharmacology of SPM 927
* 'First in patient' evaluation- where can improvements be made?
* Efficacy and tolerability in diabetic neuropathy
* Efficacy in other indications
Dr. Christine Rauschkolb
Program Director/ Medical Scientist Pain- Clinical Development
Schwarz BioSciences
11:00 Morning Coffee
11:20 NAALADase Inhibition, a Novel Pathway for Attenuating
Neuropathic Pain
* Overview: developments within the Pfizer collaboration
* GPI 5693 phase I results
* Target validation (efficacy in animal models and indications)
* Intellectual property
* NAALADase/PSMA Inhibitors and Prostate Cancer
Dr. Krystyna Wozniak
Lead Scientist on NAALADase program
Guilford Pharmaceuticals Inc
HEADACHE AND MIGRAINE PAIN- PRODUCT ANALYSIS
12:00 CASE STUDY: The Success of Anti-Migraine Drug Imitrex
* Selective 5-HT1 receptor agonists- how do they work?
* First triptan for treating migraine pain- how it has become the
market leader
* Injectable, oral or nasal spray form?
* Contraindications
Paul Strijbos
Neurology and Drug Discovery
GlaxoSmithKline
12:40 Lunch
MARKET OPPORTUNITIES
14:00 CASE STUDY: The NanoCrystal Technology Approach
* How to overcome solubility issues for pain therapeutics
* Technology performance advantages
* Can it be used as a life cycle management tool?
* A commercialised, validated solution
Gary Liversidge
Senior Director, Project Planning and Management
Elan
14:40 CASE STUDY: Peptrans, a Novel Approach to Brain
Delivery
* The BBB and drug delivery in the CNS
* Pep:trans mechanism of action
* Delivery of analgesics- an effective solution?
* Potential within the market- where can you capture a share of
the market?
Jamal Temsamani
Director, Preclinical R&D
Synt:em
15:20 Afternoon Tea
15:40 Cannabis Based Medicines- How to Optimise Pain
Treatment
* Clinical indication and pain management with cannabinoids
* GW cultivation license, possession and supply for medical
research
* R&D clinical trials- quality, safety, efficacy and phase I-III trials
* Drug delivery technologies- oro mucosal sprays, oral
formulations and inhalers
* Limitations of cannabinoid therapies- where can you fail?
* Case study: update on Sativex
Dr. Stephen Wright
Director of R&D
GW Pharma Ltd
16:20 Regulatory Limitations- Use and Distribution of Narcotic
Drugs
* Medical narcotics, the potential for misuse
* The prevention of drug abuse- new methods and control
* National drug policies- updates and how to enforce them
* Control of substances- how it limits availability for
legitimate use
Dr. Mike Reed
Director Branded Product Marketing International
Alpharma
17:00 Generics: Identifying and Overcoming the Legal and
Regulatory Challenges of the Future
* The latest developments affecting the generic drug sector and
pharmaceutical legislation
* Important legal issues- current scientific initiatives
* Potential solutions to current challenges
* Key regulatory issues in Europe
Mr. Horst Kastrup
VP Worldwide Regulatory Affairs
Viatris
17:40 Questions and Discussion
18:00 Chairman summation
18:10 Close of Conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
#####################################################################################
This email has been scanned by MailMarshal, an email content filter.
#####################################################################################
Please accept my apologies if you receive multiple copies of these 2 CfP
- ICN'05 : 4th International Conference on Networking - April 17-21, 2005 -
Reunion Island http://www.iaria.org/conferences/ICN05.html
- PWC'05 : 10th IFIP International Conference on Personal Wireless
Communications - August 25-27, 2005 Colmar, France
http://conf.uha.fr/PWC05.html
----------------------------------------------------------------------------
-----------------
CALL FOR PAPERS
4th International Conference on Networking
ICN'05
April 17-21, 2005 Reunion Island
GENERAL INFORMATION
The 2005 IEEE International Conference on Networking (ICN'05) is organized
is technically co-sponsored by IEEE/Comsoc CSIM committee, IEEE/Computer by
IEE and by the International Academy, Research and Industry Association
(IARIA). ICN'05 is organized by academic, research and industrial partners
will be held from Sunday April 17, 2005 to Thursday April 21, 2005. The
proceedings will be published by LNCS.
In order to encourage closer interaction between academic and industrial
networking research communities, we solicit both academic, research , and
industrial contributions. The 4th edition of ICN will be held in Reunion
Island. ICN 2005 will offer tutorials, plenary sessions, poster sessions,
panels, and exhibition opportunities.
TOPICS OF SPECIAL INTEREST
Topics of interest include, but are not limited to the following:
Communications switching and routing
Communications modelling
Communications security
Computer communications
Multimedia and multicast communications
Next Generation Network
Network Management, scheduling and policy
Quality of Service, reliability
Wireless Communications (Satellite, WLL, 4G, Ad Hoc, Sensor networks)
Voice over IP
Network, control and service architectures
Storage Area Networks
Access and Home Networks
Network signalling, pricing and billing
Optical networking
Distributed communications
Traffic engineering, High-Speed Networks
Telecommunication networks architectures
Performance evaluation, tools, simulation
Mobile networking and systems
Applications and case studies
Protocol design and evaluation
MPLS, GMPLS
Peer-to-Peer and overlay networking
Network middleware
Communication Theory
Signal Processing in Communications
These topics can be discussed in term of concepts, state of the art,
standards, implementations, running experiments and applications.
INSTRUCTIONS FOR AUTHORS
Only .PDF or .DOC files will be accepted for paper submission. All received
papers will be acknowledged. The files should be sent to via Only .PDF or
.DOC files will be accepted for paper submission. All received papers will
be acknowledged. The files should be sent to via
http://194.167.108.38/edas/SubmitICN.html
Papers must use single-column per page, double spacing and Times New Roman
style characters with 12-point font size. The paper size should be so as
not to exceed 8 pages when it is converted to the camera-ready format (two
columns, single spacing, Times New Roman style characters, 10-point font
size) after acceptance. All the manuscripts must be written in English. The
top of the first page of each paper should include the title of the paper,
authors' name, position, address, telephone and fax numbers, e-mail of the
author responsible for correspondence and a list of four keywords. The
deadline for submission of the paper is October 10, 2004 with notification
of acceptance by November 10, 2004. The paper should have at least 5 pages
length. Submission of camera-ready paper is by December 10, 2004.
Authors of accepted papers will later be required to submit an LNCS
copyright form, please assure that you have all necessary authorizations in
place. Authors of accepted papers will be invited to submit full-length
manuscripts for inclusion in the proceedings to be published in LNCS series
of Springer-Verlag. Final versions of accepted papers should not exceed 12
pages and must be structured according to the instructions of
Springer-Verlag. LNCS Authors Instructions sub page is available at:
http://www.springer.de/comp/lncs/authors.html.
For more information please contact: icn05(a)iaria.org
Check our Web page at http://www.iaria.org/conferences/ICN05.html or
http://193.252.19.22/conferences/ICN05.html for the latest information
concerning the conference. Best papers will be forwarded for consideration
in a special issue of a journal.
TUTORIALS AND WORKSHOPS
Tutorials and workshops provide overviews of current high interest topics.
Proposals for half of full day tutorials are due by October 10, 2004.
IMPORTANT DATES
Extended Abstract or full paper deadline October 10, 2004
Authors Notification: November 10, 2004
Camera ready, full papers due: December 10, 2004
----------------------------------------------------------------------------
----------------------------------------------------------------------------
-------------------------------------------
CALL FOR PAPERS
10th IFIP International Conference on Personal Wireless Communications
PWC'05
August 25-27, 2005, Colmar, France
GENERAL INFORMATION
PWC provides an international forum for discussions between researchers,
practitioners and students interested in new developments in mobile
computing and wireless networks. PWC'2005 is the tenth conference of this
series and is sponsored by IFIP WG 6.8, and will be held in Colmar, France.
The conference will consist of three days of scientific presentations.
TOPICS OF SPECIAL INTEREST
Topics of interest include, but are not limited to the following:
Mobile and Wireless Networking
IP-based Mobile Networks
Mobility Management
Evolution of 3G Systems
Future Generation Systems
Integration of Heterogeneous Mobile and Wireless Networks
QoS in Mobile and Wireless Networks
Ad Hoc Networks and Networks of Ad Hoc Networks
Self-organization of Wireless Networks
Personal Area Networks, Body Area Networks, and Personal Networks
Wireless Sensor Networks
Wireless LAN
Softwares for wireless systems
Ultra-Wide Band and Short-range Networks
Energy-efficient Protocols and Power Management
Security and Privacy in Mobile and Wireless Networks
AAA (Authentication, Authorization and Accounting) in Mobile and Wireless
Networks
Transport layer issues in Mobile and Wireless Networks
Analysis, Simulation and Measurement of Mobile and Wireless Networks
Cross-layer design in Mobile and Wireless Networks
Mobile and Wireless Applications
These topics can be discussed in term of concepts, state of the art,
standards, implementations, running experiments and applications.
INSTRUCTIONS FOR AUTHORS
Only .PDF or .DOC files will be accepted for paper submission. All received
papers will be acknowledged. The files should be sent via EDAS to
http://grtc2.uha.fr/edas/PaperSubmission.html
Papers must use single-column per page, double spacing and Times New Roman
style characters with 12-point font size. The paper size should be so as
not to exceed 8 pages when it is converted to the camera-ready format (two
columns, single spacing, Times New Roman style characters, 10-point font
size) after acceptance. All the manuscripts must be written in English. The
top of the first page of each paper should include the title of the paper,
authors' name, position, address, telephone and fax numbers, e-mail of the
author responsible for correspondence and a list of four keywords. The
deadline for submission of the extended abstracts or full paper is January
10, 2005 with notification of acceptance by February 15, 2005. The extended
abstracts should have at least 4 pages length. Submission of camera-ready
paper is by March 15, 2005.
For more information please contact:
Pascal LORENZ
University of Haute Alsace
34 rue du Grillenbreit
68008 Colmar, France
Phone: 33 (0)389202366 Fax: 33 (0)389202359 Mobile: 33 (0)632630204
E-mail: lorenz(a)ieee.org or pascal.lorenz(a)uha.fr
Check our Web page at http://conf.uha.fr/PWC05.html for the latest
information concerning the conference. Best papers will be forwarded for
consideration in a special issue of a journal.
TUTORIALS
Tutorials provide overviews of current high interest topics. Proposals for
half of full day tutorials are due by January 10, 2005.
IMPORTANT DATES
Extended Abstract or full paper deadline January 10, 2005
Authors Notification: February 15, 2005
Camera ready, full papers due: March 15, 2005
[Apologies for multiple copies of this announcement]
CALL FOR PARTICIPATION
RAID 2004
"Intrusion Detection and Society"
Seventh International Symposium on
Recent Advances in Intrusion Detection
Sponsored by SAP and France Telecom
Institut Eurecom, Sophia-Antipolis, French Riviera, France
September 15-17, 2004
http://raid04.eurecom.fr
RAID 2004 will be collocated with ESORICS 2004
==============================================================================
IMPORTANT NOTICE: special hotel rates have been negotiated, but the deadline
for some hotels is June 30. Please check the hotel information at:
http://raid04.eurecom.fr/Hotels.htm
==============================================================================
*******************************************
EARLY REGISTRATION DEADLINE: July 20, 2004
*******************************************
The RAID symposium brings together leading researchers and practitioners from
academia, government, and industry to discuss intrusion detection technologies
and issues from research and commercial perspectives.
This year's program features a single technical track with 14 full papers and
2 practical experience reports selected from almost 120 submissions. It also
includes invited speakers, a poster session as well as an abstracts' session.
The abstracts' session offers attendees the opportunity to present preliminary
research results or summaries of work published elsewhere. Poster presentations
of similar research results are also possible on Wednesday evening. Abstract
submissions from people not presenting posters are also welcome. Submissions
to either poster or abstract session should be sent to <dacier(a)eurecom.fr>.
For details see http://raid04.eurecom.fr/ .
PRELIMINARY PROGRAM
-------------------
Wednesday, September 15th
=========================
09.00 Registration opens
12.30 Lunch
14.00 - 14.15 Welcome
14.15 - 15.15 Invited Talk
Bruce Schneier, Counterpane Internet Security, CA, USA
15.15 - 15.45 Coffee break
15.45 - 16.45 Modelling process behaviour - Chair: Alfonso Valdes,
(SRI International, USA)
Automatic Extraction of Accurate Application-Specific
Sandboxing Policy,
Lap-chung Lam and Tzi-cker Chiueh,
Rether Networks Inc., Centereach N.Y., USA
Context Sensitive Anomaly Monitoring of Process Control
Flow to Detect Mimicry Attacks and Impossible Paths,
Haizhi Xu, Wenliang Du, and Steve J. Chapin,
Systems Assurance Institute, Syracuse University, USA
16.45 - 17.00 Break
17.00 - 18.00 Abstract session
18.00 - Poster session
Thursday, September 16th
========================
09.00 - 10.30 Detecting Worms and Viruses - Chair: John McHugh (CMU/SEI CERT, USA)
HoneyStat: Local Worm Detection Using Honeypots,
David Dagon, Xinzhou Qin, Guofei Gu, Julian Grizzard, John Levine,
Wenke Lee, and Henry Owen,
Georgia Institute of Technology, USA
Fast Detection of Scanning Worm Infections,
Jaeyeon Jung (1), Stuart E. Schechter (2), and Arthur W. Berger (1),
(1) MIT CSAIL, USA
(2) Harvard DEAS, USA.
Detecting Unknown Massive Mailing Viruses Using
Proactive Methods
Ruiqi Hu and Aloysius K. Mok,
Dept of Computer Sciences, University of Texas at Austin, USA
10.30 - 11.00 Coffee break
11.00 - 12.30 Attack and Alert Analysis - Chair: Diego Zamboni
(IBM Research, Switzerland)
Using Adaptive Alert Classification to Reduce False Positives
in Intrusion Detection,
Tadeusz Pietraszek,
IBM Zürich Research Laboratory, Switzerland.
Attack Analysis and Detection for Ad Hoc Routing Protocols
Yi-an Huang, Wenke Lee,
College of Computing, Georgia Institute of Technology, USA.
On the Design and Use of Internet Sinks for Network Abuse
Monitoring
Vinod Yegneswaran (1), Paul Barford (1), Dave Plonka (2),
(1) Dept of Computer Science, University of Wisconsin, Madison, USA,
(2) Dept of Information Technology, University of Wisconsin,
Madison, USA
12.30 - 14.00 Lunch
14.00 - 15.00 Invited Talk:
TBD
15.00 - 15.30 Coffee break
15.30 - 16.30 Practical Experience - Chair: Hakan Kvarnstrom
(TeliaSonera R&D, Sweden)
Monitoring IDS Background Noise Using EWMA Control
Charts and Alert Information
Jouni Viinikka and Herve Debar,
France Telecom R&D, Caen, France
Experience with a Commercial Deception System,
Brian Hernacki, Jeremy Bennett, Thomas Lofgren,
Symantec Corporation, Redwood City, USA
16.30 - 17.30 Poster session
Friday, September 17th
======================
09.00 - 10.30 Anomaly Detection - Chair: Christopher Kruegel,
(Technical University of Vienna, Austria)
Anomalous Payload-based Network Intrusion Detection
Ke Wang Salvatore J. Stolfo,
Computer Science Dept, Columbia University, USA
Anomaly Detection Using Layered Networks Based on Eigen
Co-occurrence Matrix
Mizuki Oka (1), Yoshihiro Oyama (2,3), Hirotake Abe (1), and
Kazuhiko Kato (1,3),
(1) University of Tsukuba, Japan,
(2) University of Tokyo, Japan,
(3) Japan Science and Technology Cooperation, Japan
Seurat: A Pointillist Approach to Anomaly Detection
Yinglian Xie (1), Hyang-Ah Kim (1), David R. O'Hallaron (1,2)
Michael K. Reiter (1,2), and Hui Zhang (1,2),
(1) Dept of Computer Science, Carnegie-Mellon University, USA
(2) Dept of Electrical and Computer Engineering,
Carnegie-Mellon University, USA
10.30 - 11.00 Coffee Break
11.00 - 12.30 Formal Analysis for Intrusion Detection - Chair: Wenke Lee
(Georgia Tech, USA)
Detection of Interactive Stepping Stones with Maximum
Delay Bound: Algorithms and Confidence Bounds
Avrim Blum, Dawn Song, Shobha Venkataraman
Carnegie Mellon University, USA.
Formal Reasoning about Intrusion Detection Systems
Tao Song (1), Calvin Ko (2), Jim Alves-Foss (3),
Cui Zhang (4), and Karl Levitt (1),
(1) Computer Security Laboratory, University of California,
Davis, USA,
(2) NAI LAbs, Network Associates Inc., Santa Clara, CA, USA,
(3) Center for Secure and Dependable Systems, University
of Idaho, USA
(4) Computer Science Dept, California State University,
Sacramento, USA.
RheoStat : Real-time Risk Management
Ashish Gehani and Gershon Kedem,
Dept of Computer Science, Duke University, USA
12.30 - 12.45 Concluding remarks
12.45 - 14.00 Lunch
ORGANIZING COMMITTEE
--------------------
General Chair: Refik Molva <refik.molva(a)eurecom.fr>
Program Chairs: Erland Jonsson <erland.jonsson(a)ce.chalmers.se>
Alfonso Valdes <valdes(a)sdl.sri.com>
Publication Chair: Magnus Almgren <almgren(a)ce.chalmers.se>
Publicity Chair: Yves Roudier <Yves.Roudier(a)eurecom.fr>
Sponsor Chair: Marc Dacier <marc.dacier(a)eurecom.fr>
PROGRAM COMMITTEE
-----------------
Tatsuya Baba (NTT Data, Japan)
Lee Badger (DARPA, USA)
Sungdeok Cha (KAIST, Korea)
Steven Cheung (SRI International, USA)
Herve Debar (France Telecom R&D, France)
Simone Fischer-Hubner (Karlstad University, Sweden)
Steven Furnell (University of Plymouth, UK)
Bill Hutchinson (Edith Cowan University, Australia)
Dogan Kesdogan (RWTH Aachen, Germany)
Chris Kruegel (Technical University of Vienna, Austria)
Hakan Kvarnstrom (TeliaSonera R&D, Sweden)
Wenke Lee (Georgia Tech, USA)
Douglas Maughan (DHS HSARPA, USA)
Roy Maxion (Carnegie Mellon University, USA)
John McHugh (CMU/SEI CERT, USA)
Ludovic Me (Supelec, France)
George Mohay (Queensland University of Technology, Australia)
Vern Paxson (ICSI and LBNL, USA)
Giovanni Vigna (UCSB, USA)
Andreas Wespi (IBM Research, Switzerland)
Felix Wu (UC Davis, USA)
Diego Zamboni (IBM Research, Switzerland)
STEERING COMMITTEE
------------------
Chair: Marc Dacier (Eurecom, France)
Herve Debar (France Telecom R&D, France)
Deborah Frincke (University of Idaho, USA)
Huang Ming-Yuh (The Boeing Company, USA)
Wenke Lee (Georgia Institute of Technology, USA)
Ludovic Me (Supelec, France)
S. Felix Wu (UC Davis, USA)
Andreas Wespi (IBM Research, Switzerland)
Giovanni Vigna (UCSB, USA)
VENUE / TRAVEL
--------------
RAID 2004 will be held on the French Riviera coast, about 20 km West of Nice
and 15 km Northeast of Cannes. The conference will take place at Institut
Eurecom / CICA, in the Sophia Antipolis science park, which can easily be
reached thanks to the nearby Nice international airport. For more
information, refer to: http://raid04.eurecom.fr/visitor_information.html
IMPORTANT DATES
---------------
Deadlines for special rates for hotels : see http://raid04.eurecom.fr/Hotels.htm
Deadline for early registration : July 20, 2004
Deadline for abstract/poster submission : August 30, 2004
(contact: Marc Dacier <Marc.Dacier(a)eurecom.fr>)
RAID conference dates : September 15-17, 2004